Neuralstem, Inc. (NYSE Amex: CUR) announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells. A reexamination request had been filed by a third-party requestor in September of 2009.
"We are of course pleased that the USPTO has upheld the patentability of all of our claims, without amendment. U.S. Patent No. 5,753,506 is a core technology patent for Neuralstem," said Richard Garr, Neuralstem's President & CEO.
Novel immune cell therapy may be a promising strategy for combating HBV infection